Wu Han, Wang Ming-Da, Zhu Jia-Qi, Li Zhen-Li, Wang Wan-Yin, Gu Li-Hui, Shen Feng, Yang Tian
Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou 310053, China.
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Naval Medical University), Shanghai 200438, China.
Pharmaceutics. 2022 Aug 23;14(9):1760. doi: 10.3390/pharmaceutics14091760.
Primary liver cancer is the seventh-most-common cancer worldwide and the fourth-leading cause of cancer mortality. In the current era of precision medicine, the diagnosis and management of liver cancer are full of challenges and prospects. Mesoporous nanoparticles are often designed as specific carriers of drugs and imaging agents because of their special morphology and physical and chemical properties. In recent years, the design of the elemental composition and morphology of mesoporous nanoparticles have greatly improved their drug-loading efficiency, biocompatibility and biodegradability. Especially in the field of primary liver cancer, mesoporous nanoparticles have been modified as highly tumor-specific imaging contrast agents and targeting therapeutic medicine. Various generations of complexes and structures have been determined for the complicated clinical management requirements. In this review, we summarize these advanced mesoporous designs in the different diagnostic and therapeutic fields of liver cancer and discuss the relevant advantages and disadvantages of transforming applications. By comparing the material properties, drug-delivery characteristics and application methods of different kinds of mesoporous materials in liver cancer, we try to help determine the most suitable drug carriers and information media for future clinical trials. We hope to improve the fabrication of biomedical mesoporous nanoparticles and provide direct evidence for specific cancer management.
原发性肝癌是全球第七大常见癌症，也是癌症死亡的第四大主要原因。在当前的精准医学时代，肝癌的诊断和治疗充满挑战与前景。介孔纳米粒子因其特殊的形态以及物理和化学性质，常被设计为药物和成像剂的特定载体。近年来，介孔纳米粒子的元素组成和形态设计极大地提高了它们的载药效率、生物相容性和生物降解性。特别是在原发性肝癌领域，介孔纳米粒子已被修饰为高度肿瘤特异性的成像造影剂和靶向治疗药物。针对复杂的临床管理需求，已确定了不同代次的复合物和结构。在这篇综述中，我们总结了肝癌不同诊断和治疗领域中这些先进的介孔设计，并讨论了转化应用的相关优缺点。通过比较不同类型介孔材料在肝癌中的材料特性、药物递送特性和应用方法，我们试图帮助确定最适合未来临床试验的药物载体和信息媒介。我们希望改进生物医学介孔纳米粒子的制备，并为特定癌症的治疗提供直接证据。
